Do not tap the pen to remove air bubbles and administer the injection per instructions
In the process of giving this medication to folks with insulin resistance and type 2 diabetes, researchers noticed that it had a pretty unique side effect, which was weight loss
Alcohol is a major cause of pancreatitis, and combining it with these medications increases the risk
BLACK BOX WARNING: GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome Type 2
Semaglutide vs Tirzepatide: The Core Differences Comparison point Semaglutide Tirzepatide Hormone pathway GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist Weight-management brand Wegovy Zepbound Diabetes brand with the same active ingredient Ozempic Mounjaro Current weight-management forms Injection and tablet Injection Direct 72-week obesity trial 13.7% mean weight reduction 20.2% mean weight reduction Notable FDA-labeled consideration Major cardiovascular event risk reduction in certain adults with established cardiovascular disease and overweight or obesity Moderate to severe obstructive sleep apnea in adults with obesity Main tolerability concern Gastrointestinal symptoms Gastrointestinal symptoms SURMOUNT-5 was a randomized phase 3b trial of adults with obesity without diabetes treated with maximum tolerated doses for 72 weeks
But if you eat a lot of onions or garlic, make sure to track your meals carefully in your diary
.png&w=3840&q=75)
